|
DYNOS for Infusion 200mg/5mL; DYNOS for Infusion 50mg/10mL
DYNOS for Infusion 200mg/5mL
DYNOS for Infusion 50mg/10mL
SCHEDULING STATUS:
S4
PROPRIETARY NAME
(and dosage form):
DYNOS for Infusion 200mg/5mL
DYNOS for Infusion 50mg/10mL
COMPOSITION:
200mg/5mL Dopamine Hydrochloride with 0,1% m/v Potassium metabisulphite
50mg/10mL Dopamine Hydrochloride with 0,1% m/v Potassium metabisulphite
PHARMACOLOGICAL CLASSIFICATION:
A.6.1 Cardiac stimulants
PHARMACOLOGICAL ACTION:
Dynos (dopamine hydrochloride) exerts a positive inotropic effect on the myocardium, acting as an agonist at beta1-adrenergic receptors. In addition, it has the capacity to release norepinephrine from nerve terminals, and this also contributes to its effects on the heart. Dynos (dopamine hydrochloride) appears to increase systolic and pulse pressure and has either no effect on or slightly increases diastolic blood pressure. Total peripheral resistance is usually unchanged when low or intermediate therapeutic doses are given. This is probably due to the ability of Dynos (dopamine hydrochloride) to reduce regional arterial resistance in the mesentery and the kidney, while producing minor increases in other vascular beds. The effect of Dynos (dopamine hydrochloride) on the renal vasculature appears to be mediated by a specific dopaminergic receptor. In relatively low doses, infusion of 2µg/kg/minute. Dynos (dopamine hydrochloride) is associated with an increase in glomerular filtration rate, renal blood flow, and sodium excretion (dopaminergic mechanism.)
INDICATIONS:
Dynos (dopamine hydrochloride) is used in the treatment of:
|
1. |
Shock unresponsive to replacement of fluid loss and especially where renal function is impaired. |
|
2. |
To correct haemodynamic imbalances associated with myocardial infarction, trauma, septic shock, and cardiac surgery. |
|
3. |
It is also used in the management of chronic refractory congestive heart failure. |
CONTRA-INDICATIONS:
Dynos (dopamine hydrochloride) should not be used in patients suffering from pheochromocytoma or in the presence of uncorrected tachyarrhythmias or ventricular fibrillation.
WARNINGS:
Abrupt discontinuation of the infusion can lead to vascular collapse.
Extreme caution must be exercised when using Dynos (dopamine hydrochloride) together with anaesthetics like cyclopropane, halothane and other halogenated anaesthetics. Patients who have been treated with monoamine oxidase (MAO) inhibitors prior to the administration of Dynos (dopamine hydrochloride) will require substantially reduced dosages.
Dynos (dopamine hydrochloride) is metabolised by MAO, and inhibition of this enzyme prolongs and potentiates the effect of Dynos (dopamine hydrochloride). The starting dose in such patients should be reduced to at least one-tenth of the usual dose.
DOSAGE AND DIRECTIONS FOR USE:
Do not use the intravenous infusion if it is darker than slightly yellow or discoloured in any other way. For intravenous infusion only.
Do not add Dynos (dopamine hydrochloride) to 5% Sodium bicarbonate or any alkaline intravenous solution, since alkalinity inactivates dopamine hydrochloride.
Dynos (dopamine hydrochloride) MUST be diluted before administration to patient. Dilution should be made just prior to administration.
Suggested Dilution:
To deliver a concentration of 200µg/mL dopamine hydrochloride:
One ampoule of Dynos for Infusion 200mg/5mL dissolved in 1litre of a suitable diluent –
or
One ampoule of Dynos for Infusion 50mg/10mL, dissolved in 250mL of suitable diluent.
Suitable diluents may contain sodium chloride and/or dextrose.
RATE OF ADMINISTRATION:
The initial rate is 2 to 5µg per kg body mass per minute, gradually increased by 5 to 10µg per kg per minute according to the patient’s blood pressure, cardiac output, and urine output. Up to 20 to 50µg per kg per minute may be required in seriously ill patients. A reduction in urine flow, without hypotension, may indicate a need to reduce the dose. To avoid tissue necrosis Dynos (dopamine hydrochloride) is best administered into a large lumen vein. Large veins of the antecubital fossa are preferred to veins in the dorsum of the hand or ankle. Less suitable infusion sites should be used only it the patient’s condition requires immediate attention. More suitable sites should be used as rapidly as possible.
SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Central effects of Dynos (dopamine hydrochloride) include fear, anxiety, restlessness, tremor, insomnia, confusion, irritability, weakness, and psychotic states, appetite reduction, nausea, vomiting. Cardiovascular effects are complex: stimulation of the alpha-adrenergic receptors produces vasoconstriction, sometimes sufficiently severe to cause gangrene when infiltrated into the digits, with resultant hypertension; the rise in blood pressure may produce cerebral haemorrhage and pulmonary oedema; reflex bradycardia, but stimulation of beta1 adrenergic receptors of the heart produce tachycardia, cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest; hypotension with dizziness and fainting, and flushing, difficulty in micturition, urinary retention, dyspnoea, altered metabolism, sweating, hypersalivation and headache.
Raised blood urea has been reported.
Extravasation of Dynos (dopamine hydrochloride) may result in tissue necrosis and sloughing. Angina may be precipitated in patients with angina pectoris. Administer with care to patients with diabetes mellitus or closed angle glaucoma.
The infusion site should be continuously monitored for free flow. Close monitoring of the following parameters - urine flow, cardiac output and blood pressure - during Dynos (dopamine hydrochloride) infusion is necessary. It is recommended that on gradual discontinuation of Dynos (dopamine hydrochloride) care should be taken to avoid undue hypotension associated with very low dosage levels where vasodilation could predominate.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
See “Side-effects and special precautions.”
In case of accidental overdosage, as evidenced by excessive blood pressure elevation, reduce rate of administration or temporarily discontinue Dynos (dopamine hydrochloride) until patient’s condition stabilises. Further treatment is symptomatic and supportive.
Management of peripheral ischemia:
To prevent sloughing and necrosis in ischemic areas, the area should be infiltrated as soon as possible with 10 to 15mL of Saline Solution containing from 5 to 10mg of Phentolamine (alpha-adrenoreceptor blocker).
A syringe with a fine hypodermic needle should be used, and the solution liberally infiltrated throughout the ischemic areas. Sympathetic blockade with Phentolamine causes local hyperemic changes if the area is infiltrated within 12hours.
IDENTIFICATION:
Dynos for Infusion 200mg/5mL: Clear colourless to slightly yellow solution in clear 5mL ampoules.
Dynos for Infusion 50mg/10mL: Clear colourless to slightly yellow solution in clear 10mL ampoules.
PRESENTATION:
Dynos for Infusion 200mg/5mL: 5mL ampoules packed in boxes of 10.
Dynos for Infusion 50mg/10mL: 10mL ampoules packed in boxes of 10.
STORAGE INSTRUCTIONS:
Protect from light.
Do not use if darker than slightly yellow or discoloured in any other way.
Store below 25°C.
Keep out of reach of children.
REGISTRATION NUMBERS:
Dynos for Infusion 200mg/5mL: Y/6.1/415
Dynos for Infusion 50mg/10mL: Y/6.1/414
NAME AND BUSINESS ADDRESS OF APPLICANT:
INTRAMED (PTY) LTD
6 Gibaud Road
Port Elizabeth
6001
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
March 1992
12-226/9-96
KOHLER C&P P.E. |
|
